ArticleBlood advances2020
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 4 syntheses or guidelines pooled it, 223 citations in OpenAlex.
- Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.Haematologica · 2026Pooled it
- A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma.Frontiers in oncology · 2024Pooled it
- Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.Annals of medicine · 2022Pooled it
- Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.Transplantation and cellular therapy · 2022Trial
- Review
- Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.Blood advances · 2026Observational
- Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy.Bone marrow transplantation · 2026Article
- Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.British journal of haematology · 2026Article
- Bridging radiotherapy before anti-CD19 CAR T-cell therapy for Large B-cell lymphoma - results from a single-center study.Radiation oncology (London, England) · 2026Article
- Current evidence and strategies for bridging therapy in CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphomas.Annals of hematology · 2026Review
- Imaging the efficacy and side effects of CAR T-cell therapy in children and young adults.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.HemaSphere · 2026Article
- Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada.Current oncology (Toronto, Ont.) · 2026Article
- A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma.Blood cancer discovery · 2026Article
- Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study.Frontiers in immunology · 2026Article
- Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma.World journal of gastroenterology · 2025Article
- An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL.Blood advances · 2025Article
- MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.British journal of haematology · 2025Article
- Combining CAR-T therapy with radiotherapy or not in refractory/relapsed diffuse large B-cell lymphoma: A comparative study.Clinical and translational radiation oncology · 2025Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
19 authors at 1 institution in 1 country.
Funding
Abstract
The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 148 LBCL patients who underwent leukapheresis for planned axicabtagene ciloleucel (axi-cel) infusion. The 55% (n = 81) of patients who received BT were more likely to have international prognostic index (IPI) score ≥3 (P ≤ .01), bulky disease (P = .01), and elevated lactate dehydrogenase (LDH; P ≤ .01). The 1-year progression-free (PFS) and overall survival (OS) rates were 40% and 65% in non-BT patients vs 21% and 48% in BT patients (P = .01 and .05, respectively). Twenty-four patients (16%) did not receive axi-cel, most commonly because of lymphoma progression (88%), despite 80% (n = 19) receiving BT. Among 124 patients who received axi-cel, 50% (n = 62) received BT with ST (n = 45), RT (n = 11), or CMT (n = 6); 1-year PFS and OS rates were not significantly different between BT and non-BT cohorts (P = .06 and .21, respectively). There was no difference in proportion of patients with IPI ≥3, limited-stage disease, or elevated LDH between ST, RT, and CMT groups. Compared with non-BT patients, 1-year PFS was inferior for ST-bridged patients (P = .01). RT-bridged patients had improved PFS compared with ST-bridged patients (P = .05). Despite the poor prognosis associated with requiring BT, RT can be an effective bridging strategy. Future studies are necessary to identify strategies that may improve access to CAR T-cell therapy and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.